Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study

BACKGROUND: Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting the benefit-risk profile of fondaparinux vs enoxaparin in a real-world group of Indian...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishna, Pinjala, Gupta, P. C., Pai, Paresh, Rai, Kumud, Rajkumar, M., Sahu, Tapish, Khan, Mohammed Yunus, Gaurav, Kumar, Mane, Amey, Pandit, Sucheta, Jain, Madhur, Subramaniyan, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844336/
https://www.ncbi.nlm.nih.gov/pubmed/34435340
http://dx.doi.org/10.1007/s40801-021-00273-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844336/
https://www.ncbi.nlm.nih.gov/pubmed/34435340
http://dx.doi.org/10.1007/s40801-021-00273-4

Ejemplares similares